Today's Date: October 22, 2014 Search | Home | Contact | Services | Patent Attorney | Patent Search | Provisional Patent Application | Patent Application | Software Patent | Confidentiality Agreements

President Obama Poised to Nominate Phil Johnson PTO Director


Written by Gene Quinn
President & Founder of IPWatchdog, Inc.
Patent Attorney, Reg. No. 44,294
Zies, Widerman & Malek
Blog | Twitter | Facebook | LinkedIn
Posted: July 1, 2014 @ 6:22 pm
Tell A Friend!




Meet Gene in Chicago
Join Gene Quinn for a Happy Hour mixer on Tues, Oct. 14, 2014, 5pm to 7pm at The Deck
CLICK HERE to RSVP.
Meet Gene in NJ
Join Gene Quinn for a Happy Hour mixer on Tuesday, Oct. 21, 2014, 5pm to 7pm at The Hyatt Morristown
CLICK HERE to RSVP. Sponsored by Innography.


Phil Johnson at IPO Inventor of the Year Ceremony, Dec. 10, 2013.

The National Journal is reporting that President Obama is poised to name Phil Johnson as Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. Johnson is currently Senior Vice-President for Intellectual Property Policy & Strategy at Johnson & Johnson.

“I’ve worked on legislative issues with Phil over the years through AIPLA,” said Nicholas Godici, former Acting Director of the USPTO and Commissioner for Patents. “Phil is very knowledgeable, fair and willing to listen to opposing views. He is certainly a well qualified candidate and in my view an excellent choice.”

Godici wasn’t the only high ranking former USPTO official to have extremely positive things to say about Phil Johnson. “I have worked with Phil Johnson on many different patent proposals over the years and have always found him to be thoughtful in his analysis of issues and willing to look at many different solutions to a problem,” said Robert Stoll, former Commissioner for Patents and current partner at Drinker Biddle. “Phil knows the patent system very well and is always seeking to improve it. He would be a great leader for the USPTO as he would need no ramp-up time and he would be able to reach reasonable compromises when others could not.”

Further, in his widely read e-mail newsletter, Hal Wegner explained: “There has been an overwhelmingly positive reaction to this development amongst insiders who see in Johnson a strong, capable leader with extensive experience both in management of patents at a major pharmaceutical company as well as many years as a first chair patent litigator.”

Indeed, Phil Johnson would not be just a good choice to run the USPTO, but he would be an outstanding choice. Johnson is well known in the industry, he is known and trusted on Capitol Hill, having testified numerous times in front of various Congressional Committees on a variety of patent issues. While I have not always agreed with Johnson on substantive issues, he is extraordinarily knowledgeable, thoughtful and highly respected. He will be an excellent Director of the USPTO, he should be appointed immediately, and the Senate should confirm him without delay.

Of course, the world of politics is never quite as simple as it ought to be. Johnson has detractors, which is almost incomprehensible, but there are those who are unhappy. There is no doubt that Johnson coming from the pharmaceutical industry will rub many the wrong way. Why? As far as I can tell there is just an irrational hatred of pharmaceutical companies as if they are evil incarnate. In some circles the words “pharmaceutical companies” can hardly be uttered without the words “big” and “evil” preceding. Like everyone else I wish the best new drugs cost less, but I also wish I would find a bottle with a genie and get three wishes! The reality is this: If we want new drugs, treatments and cures someone has to pay for it. No one is to blame for the fact that upwards of 90% of all drugs fail, and for companies to stay in business they need to make a profit. So to tar Johnson with an irrational hatred of pharmaceutical companies would be shortsighted and ridiculous. It also ignores the reality that Johnson & Johnson is far more than a pharmaceutical company. Johnson & Johnson is also the world’s largest and most diverse medical devices and diagnostics company, as well as the world’s third-largest biologics company.

Johnson’s detractors are also pointing to the fact that he was not in support of the most recent round of patent “reform,” but truthfully very few within the industry were in favor of the latest patent legislation, which is why it went down to a rather ignominious defeat. There were some within the tech sector who were pushing hard for the latest failed patent reform, such as Google, but after being in harmony with Google for many years Apple and Microsoft finally broke off and similarly did not support the failed patent legislation. Therefore, anyone who says that “tech is upset because Johnson didn’t support patent reform” is simply not being completely truthful. There were many within the tech sector who rely on patents to make their research and development worthwhile who were in agreement with Johnson. Furthermore, there is absolutely no doubt that the pharmaceutical industry will find Johnson acceptable, and the pharmaceutical industry is one of the most important of all U.S. industries.

Of course, those who are pointing to Johnson not supporting the latest failed patent legislation and trying to make the case that he is opposed to reform are grossly overstating their case for another very important reason. Johnson was one of the front line supporters of the America Invents Act (AIA), which passed in September 2011. The White House was firmly behind the AIA, with the Patent Office working with Congress, the Administration and many industry groups to get the legislation across the finish line. The White House never really got behind the latest failed patent legislation in the same way. Sure, they were giving lip service, but Obama Administration was all-in on the AIA. Thus, it is completely correct to notice that on President Obama’s primary achievement relative to patents Johnson was a major player and key influencer in the private sector. As far as I can tell there was no daylight between Johnson and the Obama Administration on the AIA. That likely played a key factor in the decision to nominate him as Director of the USPTO.

 

- - - - - - - - - -

For information on this and related topics please see these archives:

Tags: , , , , ,
Posted in: Gene Quinn, Government, IP News, IPWatchdog.com Articles, Patents, USPTO, White House

About the Author

is a Patent Attorney and the founder of the popular blog IPWatchdog.com, which has for three of the last four years (i.e., 2010, 2012 and 2103) been recognized as the top intellectual property blog by the American Bar Association. He is also a principal lecturer in the PLI Patent Bar Review Course. As an electrical engineer with a computer engineering focus his specialty is electronic and computer devices, Internet applications, software and business methods.

 

6 comments
Leave a comment »

  1. As you say, Gene, J&J is into such areas as diagnostic devices. I take it then, that those detractors who suggest that Johnson’s agenda is patents only for pharma and not for computer-implemented inventions are off the mark.

  2. MaxDrei-

    From what I can tell Johnson will have very broad based support in the industry, both the tech/research industry and within the patent community proper. The only exception will be the hard line anti-patent folks, hard line anti-pharma folks and perhaps the anti-software folks who will believe that someone from pharma has to know the importance of a strong patent portfolio. I don’t sense any detractors will have any impact, and their concern are overblown. I think Johnson is a great choice.

    -Gene

  3. J&J even has about 2 dozen business method patents.

  4. “In some circles the words “pharmaceutical companies” can hardly be uttered without the words “big” and “evil” preceding. Like everyone else I wish the best new drugs cost less, but I also wish I would find a bottle with a genie and get three wishes!”

    An appeal to reality is laudable: it is true that in a free society R&D would cost some money which customers would have to pay in order to buy the products. The public (at least those who harbour the words “evil” and “big”) should keep in mind the regulations imposed by the FDA on corporations trying to bring pharmaceuticals to the market cause the expenditure of >90 percent of their development costs. The “protections” these regulations provide over that which would arise in a free market, are arguably not worth it. If they were optional I suppose we could choose drugs by whichever company and which have undergone the testing etc. we are comfortable with, but the regulations are imposed and must be involuntarily complied with on the part of the producer and the consumer. One size fits all.

    Back to your sentiment of a genie in a bottle: unshackle the phrama industry from the FDA and you will not need that genie. Unfortunately, if freeing the industry is the goal, given the political, social, and “moral” attitudes of the public, you might want to make sure you have that genie in a bottle, or a an army of them, handy, ‘cuase it takes a lot of ice to freeze Hades.

  5. In some circles the words “pharmaceutical companies” can hardly be uttered without the words “big” and “evil” preceding. Like everyone else I wish the best new drugs cost less, but I also wish I would find a bottle with a genie and get three wishes!

    The regulations imposed by the FDA account for >90 of development costs of new pharmaceuticals.

    You don’t need a genie in a bottle to get objectively appropriate prices you just need to unshackle the pharma industry from the diktat of the FDA. Of course, to do this, given the current political, social, and “moral” views of the public, you may need to keep that genie in a bottle (or maybe a hundred of them) handy, as it will take much to freeze Hades.

  6. Gene,

    Phil Johnson as Director of the USPTO will be a huge improvement over the current “default” Director Michelle Lee. Lee generally “grinds the ax” of the anti-patent Silicon Valley.